Dogwood Therapeutics Reports Q3 Net Loss of $4.9M
Dogwood reported a Q3 2026 net loss attributable to common stockholders of $4.9 million, or $0.14 per share, versus $15.7 million, or $8.20 per share, in Q3 2025. Halneuron Phase 2b top-line results are expected in November 2026.
Dogwood reported a Q3 2026 net loss attributable to common stockholders of $4.9M, or $0.14 per share, versus $15.7M, or $8.20 per share, in Q3 2025. Halneuron Phase 2b top-line results are expected in November 2026.Material DetailsContext by AI AnalystDogwood remains a development-stage company, wi…